It should be noted that acquired clinical resistance to EGFR inhibitors in cancer is usually the result of a tertiary mutation combining the C797S mutation, MET amplification, and KRAS mutations [105], among which the C797S mutation in the EGFR is the dominant one [106]. The gene discussed is EGFR; the disease is cancer.